Supplemental New Drug Application for at-home Igalmi aims to provide a self-administered option for agitation in schizophrenia and bipolar disorder.
An older man presents with acute coronary syndrome and a large atrial myxoma, complicating diagnosis and guiding decisions on revascularization and surgery.
MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE)-- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...
Romano-Ward syndrome, the most common congenital long QT disorder, often causes exertion- or stimulus-triggered syncope and ...
The Medicity, Gurugram emphasize early diagnosis amid rising incidence of bradycardia: Our Bureau, Bengaluru Wednesday, April 1, 2026, 12:45 Hrs [IST] Medanta – The ...
The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...
Intense heat can overcome our body's ability to maintain a normal temperature, resulting in a number of illnesses.
Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...
Alpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported ...
Twice's agency, JYP Entertainment, recently announced that Dahyun will sit out upcoming performances and Chaeyoung is ...